XPOVIO® is the first XPO1 inhibitor approved in Taiwan for the treatment of adult patients with relapsed/refractory multiple myeloma (R/R MM).
- The company reports KRW373.0 billion in net sales,KRW166.3 billion in operating profit,and KRW142.4 billion in net income,reflecting year-over-year increases of 16.7%,41.2%,and 45.8%,respectively
Milestone reaffirms Hyundai Motor Group\'s commitment to safety,quality,design,and performance More than 5,000 vehicles have been tested and driven more than 20-million miles at the facility since ope
KANSAS CITY,Mo.,Feb. 13,2025-- Lockton,the world\'s largest independent insurance brokerage,is pleased to announce the establishment of a Digital Office to drive innovation in data,analytics,and tech
HONG KONG,Feb. 13,2025-- Regal Hotels International is leveraging its extensive hotel network to launch the exclusive "Long-stay Accommodation Programme" for Hospital Authority (HA) staff.
SINGAPORE,Feb. 13,2025-- Mega Matrix Inc. (NYSE American: MPU)\'s globally leading short series streaming platform,FlexTV,has launched a romantic miniseries exploring love,responsibility,and redempti
HAIKOU,China,Feb. 13,2025-- A report from Hainan International Media Center: On Feb. 12,the date of the 2025 Lantern Festival,highly anticipated fireworks and drone shows were held in Haikou,creating
PUNE,India,Feb. 13,2025-- enreapis proud to be Certified™ by Great Place To Work® for the third year in a row. The prestigious award is based entirely on what current employees say about their ex
LOS ANGELES,Feb. 13,2025-- Joico,known for its legacy of product performance and the joi(e) de vivre they bring to hair enthusiasts around the world,is celebrating an incredible milestone: 50 years o
GOTHENBURG,Sweden,Feb. 11,2025-- An independent technical review of Minesto\'s Dragon-class technology initiated in autumn 2024 has now been completed by DNV - a world leader in technology assessments